Brief: Calliditas Receives Notice Of Allowance For US Patent Application
08/04/2024 08:04
April 8 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT APPLICATION COVERING SETANAXIB IN
CANCER
TREATMENT
* NOTICE OF ALLOWANCE IS EXPECTED TO RESULT IN ISSUANCE OF A U.S. PATENT ONCE ADMINISTRATIVE
PROCESSES ARE COMPLETED
* PATENT, WHEN ISSUED, WILL HAVE AN ANTICIPATED EXPIRATION DATE IN 2038
Source text for Eikon: ID:nWkr5rWCZ7
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations